U.S. Energy Services Stock News

NYSE:SPH
NYSE:SPHGas Utilities

Assessing Suburban Propane Partners (SPH) Valuation After Mixed Recent Returns And Conflicting Fair Value Views

What recent performance says about Suburban Propane Partners Suburban Propane Partners (SPH) has seen mixed share performance recently, with a 1-day return of about a 1% decline contrasted against gains over the past week, month, and past 3 months. See our latest analysis for Suburban Propane Partners. That recent 1 day share price pullback sits against a 30 day share price return of 7.92% and a 90 day gain of 12.12%, while the 5 year total shareholder return of 91.12% shows how different the...
NYSE:CNS
NYSE:CNSCapital Markets

The Bull Case For Cohen & Steers (CNS) Could Change Following Margin Squeeze Despite Rising Revenue

Cohen & Steers, Inc. reported past fourth-quarter 2025 results, with revenue rising to US$143.8 million from US$139.78 million a year earlier, while net income declined to US$34.88 million from US$45.82 million and diluted EPS from continuing operations eased to US$0.68 from US$0.89. This combination of higher revenue but lower profitability highlights shifting cost or business mix pressures that may be important for understanding the firm’s earnings quality. We will now examine how this mix...
NYSE:TEVA
NYSE:TEVAPharmaceuticals

Assessing Teva Pharmaceutical Industries’ Valuation After Strong 2025 Earnings And Analyst Upgrades

Teva Pharmaceutical Industries (NYSE:TEVA) has drawn fresh attention after reporting full year 2025 earnings, moving from a prior net loss to US$1.4b in net income on US$17.3b in sales. See our latest analysis for Teva Pharmaceutical Industries. The recent earnings beat and return to profitability have gone hand in hand with a strong share price run, with a 90 day share price return of 66.57% and a 1 year total shareholder return of 96.43% suggesting momentum has been building over both...
NasdaqGS:EXPO
NasdaqGS:EXPOProfessional Services

A Look At Exponent (EXPO) Valuation As Earnings Optimism Builds Before February 5 Report

Exponent (EXPO) heads into its February 5 earnings report with analysts expecting higher revenue and a year over year earnings increase, and the Most Accurate Estimate sitting above the broader consensus. See our latest analysis for Exponent. Exponent’s share price has recently been choppy, with a 7 day share price return of a 4.6% decline, a 30 day share price return of 2.5%, and a current price of US$71.87. Its 1 year total shareholder return shows a 20.5% decline, which points to weaker...
NasdaqGS:TTMI
NasdaqGS:TTMIElectronic

How Raytheon’s LTAMDS Supply Deal And Index Shift At TTM Technologies (TTMI) Has Changed Its Investment Story

In late January 2026, Raytheon announced a multi-year agreement with TTM Technologies worth up to US$200 million over three years to supply radio frequency assemblies, electronic hardware and printed circuit boards for its Lower Tier Air and Missile Defense Sensor program. The deal, alongside TTM’s move from the S&P SmallCap 600 to the S&P MidCap 400, highlights the company’s growing role in defense electronics and its rising profile among mid-cap index investors. With this expanded Raytheon...
NYSE:VMI
NYSE:VMIConstruction

Valmont Industries (VMI) Valuation Check After Earnings Surprises And Upbeat Analyst Revisions

Valmont Industries (VMI) is back on many investors’ screens after a run of positive earnings surprises and upward earnings estimate revisions, a combination that has coincided with a recent 52 week high. See our latest analysis for Valmont Industries. The recent 30 day share price return of 8.22% and a 1 year total shareholder return of 38.40% suggest momentum has been building, even after a small 1 day pullback and a modest 90 day share price gain of 9.75%. If you are looking beyond...
NYSE:UAN
NYSE:UANChemicals

Did CVR Partners’ (UAN) Q4 Loss Outlook and 2025 Profit Guidance Just Reframe Its Earnings Story?

In late January 2026, CVR Partners, LP issued earnings guidance for the Fourth Quarter and full-year 2025, estimating a Q4 net loss of US$7 million to US$14 million and full-year net income of US$95 million to US$102 million. The contrast between an expected quarterly loss and a profitable full year highlights the company’s uneven earnings profile and potential seasonality in its results. We will now consider how CVR Partners’ expectation of a Q4 loss alongside full-year profitability shapes...
NasdaqGS:VEON
NasdaqGS:VEONWireless Telecom

How VEON's AI Push and Kyivstar U.S. Listing Plan Will Impact VEON (VEON) Investors

In recent weeks, VEON announced a collaboration with MindBridge to deploy AI-powered analytics across its global operations and expanded its digital footprint with a new network operations center and BuildX software and AI hub in Uzbekistan, while advancing a U.S. public offering of shares in its Ukrainian subsidiary Kyivstar. Together, these moves highlight VEON’s push to embed artificial intelligence into both its internal controls and customer-facing digital infrastructure across...
NYSE:BAX
NYSE:BAXMedical Equipment

The Bull Case For Baxter International (BAX) Could Change Following Hurricane Hit And Guidance Cut

In October 2025, Baxter International reported third-quarter adjusted earnings per share that exceeded expectations but delivered revenue below forecasts, while also cutting its full-year earnings and sales growth guidance due to hurricane-related disruptions at its North Cove facility and ongoing issues in its infusion pump portfolio. This combination of operational setbacks and reduced outlook has reinforced investor concerns about the resilience of Baxter’s core medical products business...
NasdaqGM:ZLAB
NasdaqGM:ZLABBiotechs

A Look At Zai Lab (NasdaqGM:ZLAB) Valuation As UBS Initiates Coverage And Highlights Global Pipeline Shift

UBS recently initiated coverage on Zai Lab (NasdaqGM:ZLAB), highlighting the company’s shift from a China focused commercial model toward a broader global innovation platform and renewed attention on its cancer and immunology pipeline. See our latest analysis for Zai Lab. Despite the UBS coverage putting fresh attention on Zai Lab, the share price has come under pressure, with a 90 day share price return of a 35.88% decline and a 1 year total shareholder return of a 39.37% decline, signaling...
NasdaqGS:FRME
NasdaqGS:FRMEBanks

How Stronger Earnings and Rising Credit Costs At First Merchants (FRME) Have Changed Its Investment Story

First Merchants Corporation recently reported its full-year 2025 results, with net interest income rising to US$536.01 million and net income reaching US$226 million, alongside higher basic and diluted earnings per share from continuing operations. However, the bank also disclosed a sharp increase in quarterly net charge-offs to US$6.02 million, highlighting emerging credit costs even as profitability improved. We’ll now explore how the stronger earnings alongside rising credit losses shape...
OTCPK:SKYC
OTCPK:SKYCCapital Markets

Assessing Sky Constant Century (OTCPK:SKYC) Valuation After New Board Appointments

Why the latest board appointments matter for Sky Constant Century Sky Constant Century (SKYC) has refreshed its board, adding digital commerce founder Huibin Jiang and experienced manager Zhiqing Lu, a move the company links to its search for future business opportunities. See our latest analysis for Sky Constant Century. Those board appointments have arrived during a sharp pullback, with the share price at US$7.50 after a 1 day share price return of negative 29.25% and a 7 day share price...